- current standard of care treatments for covid-19 appear to be working and the subject is clinically improving - has severe ards with a pao2/fio2 (pf ratio) ≤ 100 mmhg or spo2/fio2 ratio < 150 mmhg with peep ≥ 5cm h2o - a previous stem cell infusion unrelated to this trial - pregnant or breast feeding or planning for either during the study - suspected uncontrolled active bacterial, fungal, viral, or other infection (aside from infection with covid-19) - history of a splenectomy, lung transplant or lung lobectomy - concurrent participation in another clinical trial involving therapeutic interventions (observational study participation is acceptable) - expected survival or time to withdrawal of life-sustaining treatments expected to be < 7 days - has an existing "do not intubate" order - has undergone home mechanical ventilation (noninvasive ventilation or via tracheotomy) except for continuous positive airway pressure or bi-level positive airway pressure (cpap/bipap) used solely for sleep-disordered breathing (eg, obstructive sleep apnea) - has any significant medical condition, laboratory abnormality or psychiatric illness that in the investigator's opinion would interfere or prevent the subject from safely participating in the study

- current standard of care treatments for covid-19 appear to be working and the subject is clinically improving - has severe ards with a pao2/fio2 (pf ratio) ≤ 100 mmhg or spo2/fio2 ratio < 150 mmhg with peep ≥ 5cm h2o - a previous stem cell infusion unrelated to this trial - pregnant or breast feeding or planning for either during the study - suspected uncontrolled active bacterial, fungal, viral, or other infection (aside from infection with covid-19) - history of a splenectomy, lung transplant or lung lobectomy - concurrent participation in another clinical trial involving therapeutic interventions (observational study participation is acceptable) - expected survival or time to withdrawal of life-sustaining treatments expected to be < 7 days - has an existing "do not intubate" order - has undergone home mechanical ventilation (noninvasive ventilation or via tracheotomy) except for continuous positive airway pressure or bi-level positive airway pressure (cpap/bipap) used solely for sleep-disordered breathing (eg, obstructive sleep apnea) - has any significant medical condition, laboratory abnormality or psychiatric illness that in the investigator's opinion would interfere or prevent the subject from safely participating in the study

- current standard of care treatments for covid-19 appear to be working and the subject is clinically improving - has severe ards with a pao2/fio2 (pf ratio) ≤ 100 mmhg or spo2/fio2 ratio < 150 mmhg with peep ≥ 5cm h2o - a previous stem cell infusion unrelated to this trial - pregnant or breast feeding or planning for either during the study - suspected uncontrolled active bacterial, fungal, viral, or other infection (aside from infection with covid-19) - history of a splenectomy, lung transplant or lung lobectomy - concurrent participation in another clinical trial involving therapeutic interventions (observational study participation is acceptable) - expected survival or time to withdrawal of life-sustaining treatments expected to be < 7 days - has an existing "do not intubate" order - has undergone home mechanical ventilation (noninvasive ventilation or via tracheotomy) except for continuous positive airway pressure or bi-level positive airway pressure (cpap/bipap) used solely for sleep-disordered breathing (eg, obstructive sleep apnea)

- current standard of care treatments for covid-19 appear to be working and the subject is clinically improving - has severe ards with a pao2/fio2 (pf ratio) ≤ 100 mmhg or spo2/fio2 ratio < 150 mmhg with peep ≥ 5cm h2o - a previous stem cell infusion unrelated to this trial - pregnant or breast feeding or planning for either during the study - suspected uncontrolled active bacterial, fungal, viral, or other infection (aside from infection with covid-19) - history of a splenectomy, lung transplant or lung lobectomy - concurrent participation in another clinical trial involving therapeutic interventions (observational study participation is acceptable) - expected survival or time to withdrawal of life-sustaining treatments expected to be < 7 days - has an existing "do not intubate" order - has undergone home mechanical ventilation (noninvasive ventilation or via tracheotomy) except for continuous positive airway pressure or bi-level positive airway pressure (cpap/bipap) used solely for sleep-disordered breathing (eg, obstructive sleep apnea)

- current standard of care treatments for covid-19 appear to be working and the subject is clinically improving - a previous stem cell infusion unrelated to this trial - pregnant or breast feeding or planning for either during the study - suspected uncontrolled active bacterial, fungal, viral, or other infection (aside from infection with covid-19) - history of a splenectomy, lung transplant or lung lobectomy - concurrent participation in another clinical trial involving therapeutic interventions (observational study participation is acceptable) - expected survival or time to withdrawal of life-sustaining treatments expected to be < 7 days - has undergone home mechanical ventilation (noninvasive ventilation or via tracheotomy) except for continuous positive airway pressure or bi-level positive airway pressure (cpap/bipap) used solely for sleep-disordered breathing (eg, obstructive sleep apnea)

- current standard of care treatments for covid-19 appear to be working and the subject is clinically improving - a previous stem cell infusion unrelated to this trial - pregnant or breast feeding or planning for either during the study - suspected uncontrolled active bacterial, fungal, viral, or other infection (aside from infection with covid-19) - history of a splenectomy, lung transplant or lung lobectomy - concurrent participation in another clinical trial involving therapeutic interventions (observational study participation is acceptable) - expected survival or time to withdrawal of life-sustaining treatments expected to be < 7 days - has undergone home mechanical ventilation (noninvasive ventilation or via tracheotomy) except for continuous positive airway pressure or bi-level positive airway pressure (cpap/bipap) used solely for sleep-disordered breathing (eg, obstructive sleep apnea)